Syneos Overall health Announces Pricing of Secondary Featuring of Popular Stock – Could 04, 2021

MORRISVILLE, N.C., May possibly 03, 2021 (Globe NEWSWIRE) — Syneos Wellbeing, Inc. (Nasdaq: SYNH) (the

MORRISVILLE, N.C., May possibly 03, 2021 (Globe NEWSWIRE) — Syneos Wellbeing, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only totally built-in biopharmaceutical options business, these days declared the pricing of the previously introduced underwritten secondary supplying by affiliates of Thomas H. Lee Partners, L.P. and Arrival Worldwide Company (the “Selling Stockholders”) of an combination of 7,000,000 shares of the Company’s widespread inventory (the “Offering”). The Selling Stockholders have also granted the underwriter a 30-day solution to purchase up to 1,050,000 further shares of typical inventory. Syneos Wellness is not offering any shares and will not receive any proceeds from the proposed sale of the shares by the Offering Stockholders in the Presenting. The Offering is envisioned to near on May 6, 2021, topic to customary closing conditions.

In addition, Syneos Wellness entered into an settlement with the Providing Stockholders to repurchase an mixture of 400,000 shares of popular stock from these Promoting Stockholders in a personal transaction, concurrently with the closing of the Featuring, at the selling price at which the shares of prevalent inventory are marketed to the general public in the Providing, much less underwriting special discounts and commissions. The closing of the share repurchase is contingent on, and anticipated to come about at the same time with, the closing of the Giving, subject matter to the fulfillment of other customary problems. The closing of the Providing is not contingent on the closing of the share repurchase.

BofA Securities is acting as the sole underwriter of the Offering.

An automatic shelf registration assertion (which includes a prospectus) relating to the Supplying was submitted with the Securities and Trade Commission (“SEC”) on November 27, 2018 and became successful on submitting. Before you commit, you ought to browse the registration assertion, prospectus and other documents Syneos Overall health has manufactured accessible with the SEC for info about Syneos Health and the Giving. You may well attain these files free of charge of cost by visiting EDGAR on the SEC web page at Alternatively, copies of the prospectus and accompanying prospectus health supplement, when offered, may perhaps be obtained from:

BofA Securities, Inc.
200 North College or university Street, 3rd flooring
Charlotte NC 28255-0001
Attn: Prospectus Division
E-mail: [email protected]

This push launch shall not constitute an supply to sell or the solicitation of an provide to acquire, nor shall there be any sale of these securities in any state or other jurisdiction in which these kinds of an offer, solicitation or sale would be unlawful prior to registration or qualification below the securities regulations of any this sort of state or other jurisdiction.

Forward-Wanting Statements

Except for historical information and facts, all of the statements, expectations, and assumptions contained in this push launch are forward-seeking statements as that expression is outlined in the Private Securities Litigation Reform Act of 1995. Precise final results may possibly vary materially from individuals specific or implicit in the ahead-wanting statements. Crucial factors that could result in real effects to vary materially involve, but are not limited to: reliance on key personnel principal investigators and people typical and worldwide financial, political, and other challenges, such as forex and inventory current market fluctuations and the unsure financial surroundings any failure to comprehend the predicted rewards of the acquisitions of SHCR Holdings Corporation, or Synteract, and Illingworth Exploration Group challenges relevant to the COVID-19 pandemic the Company’s potential to sufficiently value its contracts and not overrun value estimates any adverse outcomes from the Company’s consumer or therapeutic space focus the Company’s skill to sustain or deliver new enterprise awards the Company’s skill to enhance its market place share, grow its small business, and execute its growth tactics the Company’s backlog not getting indicative of long term revenues and its ability to recognize the anticipated upcoming earnings mirrored in its backlog fluctuations in the Company’s working final results and productive profits tax charge pitfalls associated to the Company’s information and facts methods and cybersecurity improvements and costs of compliance with regulations similar to information privacy risks linked to the United Kingdom’s withdrawal from the European Union challenges connected to the Company’s transfer pricing policies failure to complete services in accordance with contractual necessities, regulatory demands and ethical considerations threats relating to litigation and authorities investigations threats related with the Company’s early section clinical amenities coverage chance dangers of liability ensuing from harm to patients achievements of investments in the Company’s customers’ business or medicine overseas forex exchange amount fluctuations challenges related with obtained corporations, which include the potential to combine obtained operations, items, and systems in our company threats relevant to the Company’s money tax expenditure and tax reform risks relating to the Company’s mental home risks connected with the Company’s acquisition system failure to realize the comprehensive benefit of goodwill and intangible belongings restructuring threat opportunity violations of anti-corruption and anti-bribery legal guidelines hazards linked to the Company’s dependence on 3rd functions downgrades of the Company’s credit score ratings competition in the biopharmaceutical solutions industry changes in outsourcing developments regulatory threats traits in the Company’s customers’ organizations the Company’s skill to continue to keep tempo with speedy technological adjust hazards related to the Company’s indebtedness fluctuations in the Company’s economic outcomes and inventory value and other danger factors set forth in the Company’s Once-a-year Report on Type 10-K for the fiscal calendar year finished December 31, 2020 and other SEC filings, copies of which are available free of cost on the SEC website at The Enterprise assumes no obligation and does not intend to update these ahead-wanting statements, besides as expected by legislation.

About Syneos Health and fitness

Syneos Wellness® (Nasdaq:SYNH) is the only completely integrated biopharmaceutical answers group. The Business, together with a Contract Exploration Business (CRO) and Contract Industrial Organization (CCO), is purpose-created to accelerate consumer functionality to address modern marketplace realities. We carry together somewhere around 25,000 scientific and professional minds with the skill to assistance buyers in extra than 110 nations. Jointly we share insights, use the most recent technologies and apply innovative company practices to pace our customers’ shipping and delivery of important therapies to people.


Primary Logo